Tag Archives: agenus

December, 2018

  • 20 December

    Gilead and Agenus Partner for Development of Immuno-Oncology Therapies

    FOSTER CITY, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 …

December, 2015

  • 30 December

    Agenus Acquires PhosImmune in $44.9 Million Deal

    LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for cancer, today announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens. The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other …

January, 2015